Exclusive (Equity) Agreement Sample Contracts
EXCLUSIVE (EQUITY) AGREEMENTExclusive (Equity) Agreement • September 19th, 2024 • Ceribell, Inc. • Electromedical & electrotherapeutic apparatus • California
This Agreement between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY ("Stanford"), an institution of higher education having powers under the laws of the State of California, and Brain Stethoscope, Inc. ("Company"), a corporation having a principal place of business at 555 Bryant St., #895, Palo Alto, California 94301, is effective on the 15th day of June, 2015 ("Effective Date").
Standard Contracts
EXCLUSIVE (EQUITY) AGREEMENTExclusive (Equity) Agreement • August 19th, 2019 • 10x Genomics, Inc. • Laboratory analytical instruments • California
This Agreement between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and EPINOMICS (“Epinomics”), a corporation having a principal place of business at 1430 O’Brien Dr, Ste D-1, Menlo Park, CA 94025, is effective on the 15th day of October, 2015 (“Effective Date”).
EX-10.1 2 d766386dex101.htm EX-10.1 [***] = Certain information, marked by brackets, has been excluded from this exhibit because such information (i) is not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed....Exclusive (Equity) Agreement • May 5th, 2020 • California
THIS AMENDMENT NO. 2 TO THE AMENDED AND RESTATED EXCLUSIVE (EQUITY) AGREEMENT (the “Amendment”) is made as of June 3, 2019 (“Amendment Effective Date”), by and between The Board of Trustees of the Leland Stanford Junior University, an institution of higher education having powers under the laws of the State of California (“Stanford”), and LogicBio Therapeutics, Inc., a Delaware corporation (“LogicBio”). Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in that certain Amended and Restated Exclusive (Equity) Agreement, dated as of January 31, 2018, by and between Stanford and LogicBio, as amended by that certain Amendment No. 1 to Amended and Restated Exclusive (Equity) Agreement, dated as of May 3, 2018 (the “Original Agreement,” and as amended by this Amendment, the “Agreement”).
EX-10.12 11 d523840dex1012.htm EX-10.12 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act...Exclusive (Equity) Agreement • May 5th, 2020 • California
This Agreement between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and Forty Seven, Inc. (“Forty Seven”), a corporation having a principal place of business at 353 Lowell Avenue, Palo Alto, California 94301, is effective on the 19th day of November, 2015 (“Effective Date”).
S09-398 : CKC EXCLUSIVE (EQUITY) AGREEMENT CONFIDENTIALExclusive (Equity) Agreement • May 24th, 2019 • BridgeBio Pharma, Inc. • Pharmaceutical preparations • California
This Exclusive (Equity) Agreement (this “Agreement”) between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and Eidos Therapeutics, Inc. (“Eidos”), a corporation having a principal place of business at 12354 Skyline Boulevard, Woodside, CA 94062, is effective on the 10th day of April, 2016 (“Effective Date”).
EX-10.9 12 d544598dex109.htm EX-10.9 S09-398 : CKC EXCLUSIVE (EQUITY) AGREEMENT CONFIDENTIAL EXCLUSIVE (EQUITY) AGREEMENTExclusive (Equity) Agreement • May 5th, 2020 • California
This Exclusive (Equity) Agreement (this “Agreement”) between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and Eidos Therapeutics, Inc. (“Eidos”), a corporation having a principal place of business at 12354 Skyline Boulevard, Woodside, CA 94062, is effective on the 10th day of April, 2016 (“Effective Date”).
AMENDED AND RESTATED EXCLUSIVE (EQUITY) AGREEMENTExclusive (Equity) Agreement • October 9th, 2018 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
This Amended and Restated Exclusive (Equity) Agreement (“Agreement”) between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and LogicBio Therapeutics, Inc. (“LogicBio”), a corporation having a principal place of business at 700 Main Street, Cambridge, MA 02139, is effective on the 31st day of January, 2018 (“Amendment Date”).
EXCLUSIVE (EQUITY) AGREEMENTExclusive (Equity) Agreement • March 8th, 2021 • California
This Agreement between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY ("Stanford"), an institution of higher education having powers under the laws of the State of California, and ("Licensee"), a corporation having a principal place of business at , is effective on the
SPECIFIC TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED. THE REDACTED MATERIAL HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE...Exclusive (Equity) Agreement • June 26th, 2020 • Alx Oncology Holdings Inc • Pharmaceutical preparations • California
This Exclusive (Equity) Agreement (“Agreement”) between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and Alexo Therapeutics International, (“Alexo”), a Cayman Islands exempted company is effective on the 24th day of March, 2015 (“Effective Date”).
EXCLUSIVE (EQUITY) AGREEMENTExclusive (Equity) Agreement • January 11th, 2021 • Bolt Biotherapeutics, Inc. • Pharmaceutical preparations • California
This Agreement between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and Bolt Therapeutics (“Bolt”), a corporation having a principal place of business at 1556 Rubino Court, Pleasanton, CA 94566, is effective on the 18th day of May, 2015 (“Effective Date”).
EXCLUSIVE (EQUITY) AGREEMENTExclusive Equity Agreement • March 8th, 2017 • California
This Agreement between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY ("Stanford"), an institution of higher education having powers under the laws of the State of California, and Medicenna Therapeutic, Inc. ("Medicenna"), a corporation having a principal place of business at 1300 – 1500 West Georgia Street, Vancouver, BC, V6G 2Z6, is effective on the _21st_ day of August, 2015 ("Effective Date").
CERTAIN CONFIDENTIAL INFORMATION (MARKED BY BRACKETS AS “[***]”) HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THE INFORMATION AS PRIVATE OR CONFIDENTIAL. Revised...Exclusive Equity Agreement • June 22nd, 2022 • Medicenna Therapeutics Corp. • Pharmaceutical preparations • California
This Agreement between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY ("Stanford"), an institution of higher education having powers under the laws of the State of California, and Medicenna Therapeutic, Inc. ("Medicenna"), a corporation having a principal place of business at 1300 – 1500 West Georgia Street, Vancouver, BC, V6G 2Z6, is effective on the 21st day of August, 2015 ("Effective Date").
EXCLUSIVE (EQUITY) AGREEMENTExclusive (Equity) Agreement • June 10th, 2019 • Atreca, Inc. • Pharmaceutical preparations • California
This Agreement between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and Atreca (“Atreca”), a corporation having a principal place of business at 2703 Witheridge Road, Belmont, CA 94002-3340, is effective on the 28 day of June, 2012 (“Effective Date”).
AMENDMENT NO. 4 TO AMENDED AND RESTATED EXCLUSIVE (EQUITY) AGREEMENTExclusive (Equity) Agreement • August 10th, 2020 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
THIS AMENDMENT NO. 4 TO THE AMENDED AND RESTATED EXCLUSIVE (EQUITY) AGREEMENT (the “Amendment No. 4”) is made as of April 29, 2020 (“Amendment No. 4 Effective Date”), by and between The Board of Trustees of the Leland Stanford Junior University, an institution of higher education having powers under the laws of the State of California (“Stanford”), and LogicBio Therapeutics, Inc., a Delaware corporation (“LogicBio”). Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in that certain Amended and Restated Exclusive (Equity) Agreement, dated as of January 31, 2018, by and between Stanford and LogicBio, as amended by that certain Amendment No. 1 dated as of May 3, 2018, and amended again by that certain Amendment No. 2 dated June 3, 2019, and amended again by that certain Amendment No. 3 dated January 29, 2020, to Amended and Restated Exclusive (Equity) Agreement (the “Original Agreement,” and as amended by this Amendment No. 4, the “Agreement”).
ContractExclusive (Equity) Agreement • May 2nd, 2024 • BridgeBio Pharma, Inc. • Pharmaceutical preparations
[***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the Registrant treats as private or confidential.
AMENDMENT NO. 6 TO AMENDED AND RESTATED EXCLUSIVE (EQUITY) AGREEMENTExclusive (Equity) Agreement • May 10th, 2021 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
THIS AMENDMENT NO. 6 TO THE AMENDED AND RESTATED EXCLUSIVE (EQUITY) AGREEMENT (the “Amendment No. 6”) is made as of March 29th, 2021 (“Amendment No. 6 Effective Date”), by and between The Board of Trustees of the Leland Stanford Junior University, an institution of higher education having powers under the laws of the State of California (“Stanford”), and LogicBio Therapeutics, Inc., a Delaware corporation (“LogicBio”). Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in that certain Amended and Restated Exclusive (Equity) Agreement, dated as of January 31, 2018, by and between Stanford and LogicBio, as amended by that certain Amendment No. 1 dated as of May 3, 2018, amended again by that certain Amendment No. 2 dated June 3, 2019, amended again by that certain Amendment No. 3 dated January 29, 2020, amended again by that certain Amendment No. 4 dated April 29, 2020, and amended again by that certain Amendment No. 5 dated October 30, 2020, to Amend
EXCLUSIVE (EQUITY) AGREEMENTExclusive (Equity) Agreement • November 6th, 2020 • AbCellera Biologics Inc. • Pharmaceutical preparations • California
This Agreement between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (‘‘Stanford”), an institution of higher education having powers under the laws of the State of California, and Lineage Biosciences, Inc. (“Company”), a corporation having a principal place of business at 3183 Porter Drive, Palo Alto CA 94304, is effective on the 11th day of February 2015 (“Effective Date”).
EXCLUSIVE (EQUITY) AGREEMENTExclusive (Equity) Agreement • September 8th, 2017 • California
This Agreement between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY ("Stanford"), an institution of higher education having powers under the laws of the State of California, and ("*****"), a corporation having a principal place of business at , is effective on the day of , 20 ("Effective Date").
AMENDMENT NO. 7 TOExclusive (Equity) Agreement • March 4th, 2022 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
AGREEMENT (the “Amendment”) is made as of December 7, 2021 (“Amendment Effective Date”), by and between The Board of Trustees of the Leland Stanford Junior University, an institution of higher education having powers under the laws of the State of California (“Stanford”), and LogicBio Therapeutics, Inc., a Delaware corporation (“LogicBio”) (together, the “Parties”). Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in that certain Amended and Restated Exclusive (Equity) Agreement, dated as of January 31, 2018, by and between Stanford and LogicBio, as amended by that certain Amendment No. 1 dated as of May 3, 2018, amended again by that certain Amendment No. 2 dated June 3, 2019, amended again by that certain Amendment No. 3 dated January 29, 2020, amended again by that certain Amendment No. 4 dated April 29, 2020, amended again by that certain Amendment No. 5 dated October 30, 2020, and as amended again by that certain Amendment No. 6 dated March 2
AMENDMENT TO EXCLUSIVE (EQUITY) AGREEMENTSExclusive (Equity) Agreement • June 22nd, 2022 • Medicenna Therapeutics Corp. • Pharmaceutical preparations • California
This is an amendment (this “Amendment”) to the Exclusive (Equity) Agreement for Stanford dockets S11-072 and S11-184 (the “Agreement”) entered into as of August 21, 2015 between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and Medicenna Therapeutics, Inc. (“Medicenna”), a corporation having a principal place of business at 2 Bloor St. W, 7th Floor, Toronto, Ontario M4W 3E2 (each a “Party” and collectively the “Parties”).
CERTAIN CONFIDENTIAL INFORMATION (MARKED BY BRACKETS AS “[***]”) HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THE INFORMATION AS PRIVATE OR CONFIDENTIAL. Revised...Exclusive Equity Agreement • June 22nd, 2022 • Medicenna Therapeutics Corp. • Pharmaceutical preparations • California
This Agreement between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY ("Stanford"), an institution of higher education having powers under the laws of the State of California, and Medicenna Therapeutic, Inc. ("Medicenna"), a corporation having a principal place of business at 1300 – 1500 West Georgia Street, Vancouver, BC, V6G 2Z6, is effective on the _21st_ day of August, 2015 ("Effective Date").
EXCLUSIVE (EQUITY) AGREEMENTExclusive (Equity) Agreement • June 24th, 2021 • Consonance-HFW Acquisition Corp. • Biological products, (no disgnostic substances) • California
This Agreement between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and Surrozen (“Surrozen”), a corporation having a principal place of business at 1700 Owens St., Ste 500, San Francisco, CA, 94158, is effective on the 23rd day of March, 2016 (“Effective Date”).
EXCLUSIVE (EQUITY) AGREEMENTExclusive (Equity) Agreement • November 27th, 2020 • Longview Acquisition Corp. • Blank checks • California
This Agreement between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and Butterfly Network, Inc. (“Butterfly”), a corporation having a principal place of business at 530 Old Whitfield Street, Guilford, CT 06473, is effective on the 28 day of June, 2013 (“Effective Date”).
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...Exclusive (Equity) Agreement • March 26th, 2021 • Akoya Biosciences, Inc. • Laboratory analytical instruments • California
This Agreement between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and Akoya Biosciences, Inc. (“AKOYA”), a Delaware corporation having a principal place of business at 360 Post Street, Suite 601, San Francisco, California, is effective on the 17th day of November, 2015 (“Effective Date”).
AMENDMENT TO EXCLUSIVE (EQUITY) AGREEMENTExclusive (Equity) Agreement • June 10th, 2019 • Atreca, Inc. • Pharmaceutical preparations
This AMENDMENT TO THE EXCLUSIVE (EQUITY) AGREEMENT (the “Amendment”) is effective as of May 24, 2018 (the “Amendment Effective Date”) by and between ATRECA, INC., a Delaware corporation, located at 500 Saginaw Drive, Redwood City, California 94063-4750 (“Atreca”), and THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, an institution of higher education having powers under the laws of the State of California (“Stanford”).
CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT NO. 2 TO EXCLUSIVE (EQUITY) AGREEMENTExclusive (Equity) Agreement • March 3rd, 2022 • Atreca, Inc. • Pharmaceutical preparations • California
This AMENDMENT NO. 2 TO EXCLUSIVE (EQUITY) AGREEMENT (“Amendment”) is effective as of July 2, 2020 (“Amendment Effective Date”), by and between The Board of Trustees of the Leland Stanford Junior University, an institution of higher education having powers under the laws of the State of California (“Stanford”), and Atreca, Inc., a Delaware corporation having an address at 450 East Jamie Court, South San Francisco, CA 94080 (“Atreca”). Each of Stanford and Atreca are referred to in this Amendment as a “Party” and together, the “Parties.”
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT LOGICBIO THERAPEUTICS, INC. TREATS AS PRIVATE OR CONFIDENTIAL AMENDMENT NO. 5 TO AMENDED AND RESTATED...Exclusive (Equity) Agreement • March 15th, 2021 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
THIS AMENDMENT NO. 5 TO THE AMENDED AND RESTATED EXCLUSIVE (EQUITY) AGREEMENT (the “Amendment No. 5”) is made as of October 30, 2020 (“Amendment No. 5 Effective Date”), by and between The Board of Trustees of the Leland Stanford Junior University, an institution of higher education having powers under the laws of the State of California (“Stanford”), and LogicBio Therapeutics, Inc., a Delaware corporation (“LogicBio”). Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in that certain Amended and Restated Exclusive (Equity) Agreement, dated as of January 31, 2018, by and between Stanford and LogicBio, as amended by that certain Amendment No. 1 dated as of May 3, 2018, and amended again by that certain Amendment No. 2 dated June 3, 2019, amended again by that certain Amendment No. 3 dated January 29, 2020, and amended again by that certain Amendment No. 4 dated April 29, 2020, to Amended and Restated Exclusive (Equity) Agreement (the “Original Agreem
AMENDMENT TO EXCLUSIVE (EQUITY) AGREEMENTSExclusive (Equity) Agreement • June 22nd, 2022 • Medicenna Therapeutics Corp. • Pharmaceutical preparations • California
This is an amendment (this “Amendment”) to the Exclusive (Equity) Agreement for Stanford dockets S10-200 and S14-174 (the “Agreement”) entered into as of August 21, 2015 between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and Medicenna Therapeutics, Inc. (“Medicenna”), a corporation having a principal place of business at 2 Bloor St. W, 7th Floor, Toronto, Ontario M4W 3E2 (each a “Party” and collectively the “Parties”).
AMENDMENT NO. 3 TO AMENDED AND RESTATED EXCLUSIVE (EQUITY) AGREEMENTExclusive (Equity) Agreement • March 16th, 2020 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
THIS AMENDMENT NO. 3 TO THE AMENDED AND RESTATED EXCLUSIVE (EQUITY) AGREEMENT (the “Amendment No. 3”) is made as of January 29, 2020 (“Amendment No. 3 Effective Date”), by and between The Board of Trustees of the Leland Stanford Junior University, an institution of higher education having powers under the laws of the State of California (“Stanford”), and LogicBio Therapeutics, Inc., a Delaware corporation (“LogicBio”). Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in that certain Amended and Restated Exclusive (Equity) Agreement, dated as of January 31, 2018, by and between Stanford and LogicBio, as amended by that certain Amendment No. 1 dated as of May 3, 2018, and amended again by that certain Amendment No. 2, dated June 3, 2019, to Amended and Restated Exclusive (Equity) Agreement (the “Original Agreement,” and as amended by this Amendment No. 3, the “Agreement”).
AMENDMENT NO. 3 TO EXCLUSIVE (EQUITY) AGREEMENTExclusive (Equity) Agreement • June 24th, 2021 • Consonance-HFW Acquisition Corp. • Biological products, (no disgnostic substances) • California
THIS AMENDMENT NO. 3 TO THE EXCLUSIVE (EQUITY) AGREEMENT (this “Amendment”) dated as of January 19, 2021 (the “Amendment Date”), is entered into between Surrozen, Inc., a Delaware corporation (hereinafter, “Surrozen”), having offices at 171 Oyster Point Blvd., Suite 400, South San Francisco, CA 94080 and Board of Trustees of the Leland Stanford Junior University (hereinafter, “Stanford”), an institution of higher education, having powers under the laws of the State of California, and having offices at 3000 El Camino Real, Building 5, Suite 300, Palo Alto, CA 94306-2100, with respect to the following facts:
AMENDMENT NO. 1 TO AMENDED AND RESTATED EXCLUSIVE (EQUITY) AGREEMENTExclusive (Equity) Agreement • March 16th, 2020 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
THIS AMENDMENT NO. 1 TO THE AMENDED AND RESTATED EXCLUSIVE (EQUITY) AGREEMENT (the “Amendment”) is made as of May 3, 2018, by and between The Board of Trustees of the Leland Stanford Junior University, an institution of higher education having powers under the laws of the State of California (“Stanford”), and LogicBio Therapeutics, Inc., a Delaware corporation (“LogicBio”). Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in that certain Amended and Restated Exclusive (Equity) Agreement, dated as of January 31, 2018, by and between Stanford and LogicBio (the “Original Agreement,” and as amended by this Amendment, the “Agreement”).
